Abstract #844: Can B-Lymphocyte Stimulator (BLYS) be a Serological Prognostic Marker in Patients with Neuroendocrine Tumors?

Authors :: Elio Tonutti
Franco Grimaldi
Cinzia Pistis
Martina Fabris
Veronica Tonelli
Francesco Curcio
Fabio Vescini
Cecilia Motta
Claudia Cipri
Source :: Endocrine Practice. 22:184-185
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Endocrinology
business.industry
Endocrinology, Diabetes and Metabolism
Immunology
medicine
In patient
General Medicine
Neuroendocrine tumors
B-cell activating factor
medicine.disease
business
B Lymphocyte Stimulator
Serology

Full Text Access

Tools